Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Feb 17, 2014
Clinical News
Adult stem cells: Phase II data
...43% with high-dose MPCs, 28% with saline a and 30% with HA (p=0.09 for high-dose
MPC group
...
Read More
BioCentury
|
Jan 14, 2013
Clinical News
NeoFuse: Phase II data
...30-40% lower estimated blood loss during surgery vs. bone autograft (p<0.05 for the 25 million
MPC group
...
Read More
BioCentury
|
Jan 28, 2002
Financial News
BioVisioN raises $13.3 million
...in a private round led by Heidelberg Innovation. Other investors included Nextech Venture; IVEC; the
MPC Group
...
Read More
Items per page:
10
1 - 3 of 3
BioCentury
|
Feb 17, 2014
Clinical News
Adult stem cells: Phase II data
...43% with high-dose MPCs, 28% with saline a and 30% with HA (p=0.09 for high-dose
MPC group
...
Read More
BioCentury
|
Jan 14, 2013
Clinical News
NeoFuse: Phase II data
...30-40% lower estimated blood loss during surgery vs. bone autograft (p<0.05 for the 25 million
MPC group
...
Read More
BioCentury
|
Jan 28, 2002
Financial News
BioVisioN raises $13.3 million
...in a private round led by Heidelberg Innovation. Other investors included Nextech Venture; IVEC; the
MPC Group
...
Read More
Items per page:
10
1 - 3 of 3
Previous page
Next page
